Takara Bio

Shiga, JP
CAR-T Lentiviral
8 confirmed programs · 4 sponsors · Last scored 2026-04-02
58.5
Signal Score
○ FDA Inspections ✓ Clinical Trials (8) ○ SEC Filings ✓ Press (4) ○ EMA GMP ○ MHRA GMP

Quick Facts: Takara Bio

Signal Score
58.5/100 (as of 2026-04-02)
Quality Compliance
Assessment pending
Headquarters
Shiga, JP
Modalities
CAR-T, Lentiviral
Active Programs
8 confirmed from ClinicalTrials.gov across 4 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 56.2
8 active programs across 4 sponsors
Modalities: Lentiviral, CAR-T
5 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
8 active programs across 4 sponsors · Modalities: Lentiviral, CAR-T · 5 programs in advanced phases (Phase 2/3)
Programs 8
Sponsors4
ModalitiesCAR-T, Lentiviral
8 active programs across 4 sponsors
Modalities: Lentiviral, CAR-T
5 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07174427 Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel;... PHASE3 Recruiting
NCT05963217 Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen... PHASE1 Recruiting
NCT03250325 Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced... PHASE1/PHASE2 Completed
NCT03155191 Study of TBI-1501 for Relapsed or Refractory Acute... PHASE1/PHASE2 Active Not Recruiting
NCT02418598 AADC Gene Therapy for Parkinson's Disease PHASE1/PHASE2 Terminated
NCT02366546 Investigator Initiated Phase 1 Study of TBI-1301 PHASE1 Unknown
NCT02134262 Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR... PHASE1/PHASE2 Unknown
NCT02096614 Investigator Initiated Phase 1 Study of TBI-1201 PHASE1 Completed
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
1 manufacturing site: Shiga, JP
Modalities: CAR-T, Lentiviral
Capacity assessment: 60.0/100
Sites: Shiga, JP
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
Recent Press4 articles
1 manufacturing site: Shiga, JP
Modalities: CAR-T, Lentiviral
Capacity assessment: 60.0/100

Recent News 4 articles

general 2026-03-31
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation - BioSpace
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation  BioSpace
Source →
general 2026-03-30
Takara Bio USA and Hamilton Partner for Automated NGS Library Prep - San Jose Today - National Today
Takara Bio USA and Hamilton Partner for Automated NGS Library Prep - San Jose Today  National Today
Source →
general 2026-03-27
TAKARA BIO PB Ratio: 1.36 — 56% Below Median - gurufocus.com
TAKARA BIO PB Ratio: 1.36 — 56% Below Median  gurufocus.com
Source →
partnership 2026-02-26
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026 - BioSpace
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026  BioSpace
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Lentiviral CDMOs →

Similar CDMOs

AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.2
CAR-T, Cell Therapy, AAV, Lentiviral
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 92.2
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
Catalent
Somerset, NJ (Now Novo Holdings)
Signal Score: 81.0
AAV, CAR-T, Lentiviral, Plasmid DNA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
Signal Score: 79.7
AAV, CAR-T, Lentiviral, Plasmid
OmniaBio
Hamilton, ON
Signal Score: 79.5
AAV, Lentiviral, CAR-T, Cell Therapy